Abstracts tagged "inflammation and spondylarthropathy"

Abstract Number: 2612 • 2012 ACR/ARHP Annual Meeting
Localisation of Bone Marrow Edema in Sacroiliac Joints in Spondyloarthritis Patients: Does the Site of Lesions Change Over a 3-Month Period?
Manouk de Hooge¹, Rosaline van den Berg¹, Monique Reijnierse², Victoria Navarro-Compán¹, Floris van Gaalen¹, Tom Huizinga¹ and Désirée van der Heijde¹, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Radiology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: A positive MRI at baseline is a strong predictor for a positive follow-up MRI1. But many questions about the volatility of the lesions over…
Abstract Number: 2216 • 2012 ACR/ARHP Annual Meeting
Cardiovascular Risk Assessment in Spondyloarthritis Using the Score Chart and Reclassification by Presence of Plaques On Ultrasonography
Jl Rosales-Alexander¹, Juan Salvatierra¹, César Magro Checa¹, Jesús Cantero Hinojosa² and Enrique Raya Álvarez¹, ¹Rheumatology, University Hospital San Cecilio, Granada, Spain, ²Internal Medicine, University Hospital San Cecilio, Granada, Spain
Background/Purpose: Increased cardiovascular (CV) risk have been described in patients with rheumatic diseases including spondyloarthritis (SpA). Besides traditional CV risk factors, disease specific factors have…
Abstract Number: 1705 • 2012 ACR/ARHP Annual Meeting
Effect of Certolizumab Pegol On Inflammation of Spine and Sacroiliac Joints in Patients with Axial Spondyloarthritis: 12 Week Magnetic Resonance Imaging results of a Phase 3 Double Blind Randomized Placebo-Controlled Study
Désirée van der Heijde¹, Walter P. Maksymowych², Robert B. M. Landewé³, Christian Stach⁴, Bengt Hoepken⁴, Andreas Fichtner⁴, Danuta Kielar⁵ and Jürgen Braun⁶, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Department of Medicine, University of Alberta, Edmonton, AB, Canada, ³Academic Medical Center/University of Amsterdam & Atrium Medical Center, Amsterdam, Netherlands, ⁴UCB Pharma, Monheim am Rheim, Germany, ⁵UCB Pharma, Brussels, Belgium, ⁶Rheumazentrum Ruhrgebiet, Herne, Germany
Background/Purpose: Axial spondyloarthritis (axSpA) includes both ankylosing spondylitis (AS) and non-radiographic axSpA (nr-axSpA) and is defined by the ASAS criteria.1 It is characterized by bone…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].